Showing 1911-1920 of 2105 results for "".
- Autologous Mesenchymal Stem Cells Expressing Neurotrophic Factors Improved Function and Biomarkers in Progressive Multiple Sclerosishttps://practicalneurology.com/news/autologous-mesenchymal-stem-cells-expressing-neurotrophic-factors-improved-function-and-biomarkers-in-progressive-multiple-sclerosis/2469728/In a trial (NCT03799718) of autologous neurotrophic mesenchymal stem cells (MSC-NTF) (NurOwn; BrainStorm Cell Therapeutics, New York, NY), 18 individuals with progressive MS were treated, and 16 c
- Ocrelizumab Reduced Disability Progression in Relapsing Multiple Sclerosis and Primary Progressive Multiple Sclerosishttps://practicalneurology.com/news/ocrelizumab-reduced-disability-progression-in-relapsing-multiple-sclerosis-and-primary-progressive-multiple-sclerosis/2469717/Individuals with relapsing multiple sclerosis (RMS) who were treated with ocrelizumab (Ocrevus; Genentech, South San Francisco, CA) for 7.5 years vs 5.5 years (after ~2 years on interferon β) had a 35% lower chance of needing a walking aid (5.2% vs. 7%, 95% CI: 0.44–0.97; P=.034). The
- First Participant Treated With Vidofludimus in Phase 2 Trialhttps://practicalneurology.com/news/phase-3-vidofludimus-calcium-trial-initiates-first-participant-dosage/2469705/A phase 2 trial for vidofludimus calcium (VFC)(IMU-838; Immunic, New York, NY) has been initiated with the first participant treated for progressive multiple sclerosis (PMS). The CALLIPER trial (NCT05
- Huntington Disease Trial of New Antisense Oligonucleotide Therapy Begins Dosinghttps://practicalneurology.com/news/huntington-disease-trial-of-new-antisense-oligonucleotide-therapy-begins-dosing/2469685/The first participant has been treated in the phase 1b/2a SELECT-HD clinical trial evaluating an investigational stereopure antisense oligonucleotide (ASO) (WVE-003; Wave Life Sciences, Cambridge, MA) as a treatment for Huntington disease (HD). The ASO is designed to target a single nucleotide po
- New Guideline Provides Clinical Recommendations for Excessive Daytime Sleepinesshttps://practicalneurology.com/news/new-guideline-provides-clinical-recommendations-for-excessive-daytime-sleepiness/2469682/Clinical practice guidelines for the treatment of central disorders of hypersomnolence have been updated by the American Academy of Sleep Medicine (AASM), for the first time since 2007, with new recommendations. The guideline is available online in the Journal of Clinical Sleep Medicine and provi
- Game-Based Digital Therapy for Individuals With Multiple Sclerosis Reduces Anxietyhttps://practicalneurology.com/news/game-based-digital-therapy-for-individuals-with-multiple-sclerosis-reduces-anxiety/2469670/Use of a game-based digital therapy (Personal Zen; Wise Therapeutics, New York, NY) reduced symptoms of anxiety in individuals with multiple sclerosis (MS). The digital therapy requires a prescription and uses adaptive, personalized gameplay to address mental health needs, and can serve as an at-
- Survey for Chronic Inflammatory Demyelinating Polyneuropathy Shows High Rate of Misdiagnosis and Strong Treatment Responsehttps://practicalneurology.com/news/survey-for-chronic-inflammatory-demyelinating-polyneuropathy-shows-high-rate-of-misdiagnosis-and-strong-treatment-response/2469664/A survey of individuals with chronic inflammatory demyelinating polyneuropathy (CIDP) showed high rates of misdiagnosis but also good response to treatment. According to the results, 70% of respondents were diagnosed at age 41 to 65, and more than 54% stated it took more than a year to be correct
- FDA Approves Avalglucosidase Alfa for Pompe Diseasehttps://practicalneurology.com/news/fda-approves-avalglucosidase-alfa-for-pompe-disease/2469662/The Food and Drug Administration (FDA) approved avalglucosidase alfa (avalGA) (Nexviazyme; Sanofi, Bridgewater, NJ) for the treatment of individuals age 1 year and up with late-onset Pompe disease (LOPD). Treatment of people with LOPD with avalGA improved respiratory function and timed walk
- Clinical Trials of Vidofludimus for Relapsing and Progressive Multiple Sclerosis Get Green Lighthttps://practicalneurology.com/news/clinical-trials-of-vidofludimus-for-relapsing-and-progressive-multiple-sclerosis-get-green-light/2469628/The Food and Drug Administration (FDA) cleared phase 3 ENSURE (NCT identifier not yet available) and phase 2 CALLIPER (NCT identifier not yet available) clinical trials of vidofludimus calcium (VFC)(IMU-83
- FDA Grants Orphan Drug Exclusivity for Mixed Salts Oxybate for Cataplexy or Excessive Daytime Sleepinesshttps://practicalneurology.com/news/fda-grants-orphan-drug-exclusivity-for-mixed-salts-oxybate-for-cataplexy-or-excessive-daytime-sleepiness/2469624/The Food and Drug Administration has granted 7 years of Orphan Drug Exclusivity for mixed salts oxybate (Xywav; Jazz Pharmaceuticals, Philadelphia, PA) for the treatment of cataplexy or excessive daytime sleepiness (EDS) caused by narcolepsy in individuals age 7 years or more. FDA